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Background: Provider recommendation is a signiﬁcant predictor of HPV vaccine uptake. Prior research
suggests that concerns regarding risk compensation could cause some providers to hesitate re-
commending the HPV vaccine.
Methods: During 15–30 min semi-structured interviews in early 2015, 22 U.S. pediatric providers were
asked about their beliefs regarding sexual risk compensation and cervical cancer screening following
HPV vaccination. Providers were asked if these beliefs result in reservations recommending the vaccine.
Interviews were audio-recorded, transcribed, and analyzed using inductive content analysis.
Results: None of the providers believed the HPV vaccine would result in risky sexual behavior. Half in-
dicated it was better to start vaccination early, before sexual activity was a worry. Others noted that
patients’ risky behavior decisions happen independently of vaccination. When providers were asked if
they were concerned about decreased cervical cancer screening, half said they did not know and some
stated they had never thought about it before. The main themes addressed were the signiﬁcant time
lapse between vaccination and screening and that women tend to get over-screened as opposed to
under-screened.
Conclusion: Providers were generally in favor of HPV vaccination and do not perceive risk compensation
as a barrier to HPV recommendation.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2015 the Centers for Disease Control and Prevention (CDC)
estimated that approximately 79 million Americans are currently
infected with Human Papillomavirus (HPV) and 14 million new
infections occur every year, making it the most common sexually
transmitted infection (STI) in the U.S. [1]. Infection with HPV is a
causal factor for serious health issues including cervical cancer,
anal cancer, penile cancer, oropharyngeal cancers, genital warts,
and recurrent respiratory papillomatosis [2].
Currently, there are three different vaccines against HPV li-
censed by the U.S. Food and Drug Administration (FDA). TheB.V. This is an open access article u
g),
.org (B.E. Dixon),
ck.com (A. Kulkarni),current vaccine has the potential to prevent up to 80–90% of cer-
vical cancers, 90% of genital warts [3], and is routinely re-
commended by the Advisory Committee on Immunization Prac-
tices (ACIP) for both males and females age 11–12 [4,5]. Despite the
potential beneﬁts, HPV vaccination rates in the U.S. remain very
low [6]. In 2014, only 60.0% of adolescent girls and 41.7% of ado-
lescent boys between the ages of 13 and 17 received one or more
doses in the HPV vaccine series [7]. The numbers are even lower
for series completion (39.7% of girls and 21.6% of boys) Barriers to
HPV vaccination include cost of the vaccine, lack of knowledge
about HPV transmission, and parental concerns about vaccinating
their children against a sexually transmitted infection (STI) [8].
Recent research has shown that a sizeable portion of physicians do
not strongly endorse the HPV vaccine (27%) and do not deliver
timely recommendations (26% for girls, 39% for boys) [9]. This is of
particular concern because one of the strongest predictors of
vaccine uptake is healthcare provider (HCP) recommendation and
a lack of HCP recommendation has been listed as a reason for non-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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One concern among parents, clinicians, and public health ofﬁ-
cials that has received particular attention in the media is that the
introduction of the HPV vaccine may lead to risk compensation.
Risk compensation is the idea that each person has an individual
level of tolerance for the amount of risk they will take and if some
aspect of risk is reduced, he or she will increase risky behavior in
order to get back up to that set point [15,16]. Opponents of the
HPV vaccine have argued that vaccination could cause adolescents
to engage in more risky sexual behavior due to a perceived de-
creased risk of sexually transmitted infections [17], a concern that
has no empirical support [18]. Furthermore, an additional area
addressed when risk compensation is examined is a possibility
that women who have received the HPV vaccine may be less likely
to get screened for cervical cancer, or may cease cervical cancer
screening altogether [19–21]. It is therefore important to under-
stand if HCPs are concerned about risk compensation and if these
concerns affect their HPV vaccination practices.
The purpose of this study was to: 1) understand HCP beliefs
surrounding risk compensation with regards to sexual behaviors;
2) understand HCP beliefs surrounding risk compensation with
regards to cervical cancer screening practices; and 3) ascertain
how these beliefs affect HCP HPV vaccination recommendation
practices.2. Methods
2.1. Study participants
As part of a larger study examining computerized HCP re-
minders for HPV vaccination, we conducted semi-structured,
qualitative interviews from January to March 2015. The study was
approved by the Indiana University Institutional Review Board and
more information on the larger study can be found at Clin-
icalTrials.gov (Identiﬁer: NCT02551887). Participants for this study
were pediatrician HCPs working in publicly-funded urban health
clinics, had patients between the ages of 11–12 who were in need
of vaccination, and consented to be interviewed. All eligible HCPs
were contacted via e-mail. Two additional follow-up e-mails were
sent to each participant who did not respond to the initial e-mail.
A total of 39 HCPs were eligible to be interviewed and 22 (56.4%)
consented and completed the interview. Participants were re-
cruited until saturation was reached, that is, until we acquired
limited new information from the interviews [22].
2.2. Interviews and data analysis
Qualitative methodology is ideal when exploring an area where
little is known because it allows the investigators to identify, via
in-depth analysis, personal and contextual factors [23]. The ma-
jority of the interviews were conducted face-to-face (n¼20), but
some were conducted over the phone if the HCP could not meet in
person (n¼2). All interviews were one-on-one and conducted by
the lead author (MLK). Interviews lasted 15–30 min, and partici-
pants were compensated with a $50 gift card. After providing brief
information regarding the study, participants were asked about
their general beliefs regarding HPV and HPV vaccination. They
were further asked additional questions for the larger study per-
taining to computerized reminders prompting HPV vaccine re-
commendation. Finally, HCPs were asked: 1) if they believe their
patients will practice riskier sexual behaviors (for both male and
female patients) after they are vaccinated, 2) if they believe vac-
cination will result in their female patients feeling they do not
need to get screened for cervical cancer, and 3) if either of these
issues affect HCP recommendation. Along with these questions,demographic characteristics (including sex, race/ethnicity, and
years in practice) as reported during the interview were also
collected.
Interviews were audio-recorded with a hand-held digital re-
corder and transcribed verbatim by a professional transcriptionist.
They were hand-coded and analyzed using inductive content
analysis [24]. Transcripts of the interviews were read in-
dependently by two coauthors (MLK & SW) using open-coding to
identify meaningful themes and categories. Once categories were
developed, coders developed subcategories of comments. The
codes were reviewed after each coding phase and areas of dis-
agreement between coders were resolved through discussion until
there was at least 80% agreement within each category.3. Results
3.1. Study sample
We contacted a total of 39 HCPs, of which 21 physicians and
1 nurse practitioner (56% response rate; 17 female, 5 male), agreed
to be interviewed. All HCPs specialized in pediatrics. It is worth
noting that the nurse practitioner's responses were not qualita-
tively different from the physicians’ responses. Participants aver-
aged 14 years in practice and the majority (n¼14) identiﬁed as
non-Hispanic White, with 4 reporting their race as non-Hispanic
Black, 3 Hispanic, and 1 Asian.
The hospital system, Eskenazi Health, is one of the ﬁve largest
safety net health systems in the U.S. The health system contains a
315-bed hospital and nine community health centers located
across the metropolitan area of Indianapolis. Each community
health center provides adult primary care, pediatrics, obstetrics,
gynecology, and mental health services.
The 11–12 year old patient population served by these provi-
ders, that is, the population of interest to for increasing HPV vac-
cine uptake, is 50.1% female and the largest proportion (49.3%)
identify as Black while 12.6% identify as White, 26.7% identify as
Hispanic, and 11.4% identify as Other or unknown. Over 70% of the
pediatric patient population in this healthcare system is on Med-
icaid, 3.3% receive charity care, and 5.5% self-pay.
3.2. Sexual risk compensation
None of the HCPs indicated they believe that getting vaccinated
against HPV would lead a young adolescent to engage in riskier
sexual behavior. Within that question, ﬁve of the HCPs pointed the
interviewer to research supporting their opinion. Instead of stating
their personal beliefs, they would state evidence from the litera-
ture by saying, for example, “I think that's been shown in not just
one publication but multiple publications to not be true (female,
10 years in practice).” For a list of themes and other exemplar
quotes, see Table 1.
3.2.1. Belief that sexual behaviors are independent of vaccination
Half of HCPs speciﬁcally mentioned they feel it is better to start
vaccinating their patients before sexual activity was a worry. Some
felt that this was important in order to ensure their patients are
protected before they are sexually active and HCPs would com-
municate this by saying, “This is about the idea that the vast ma-
jority of people at some point in their life are sexually active. And
so we want this protection before that starts (male, 6 years in
practice).” While other HCPs prefer to vaccinate before sexual ac-
tivity is a worry, so they do not have to talk about sexual activity in
the context of vaccination. For example, one HCP said, “If some-
body asks me—like I usually talk about how [HPV] is the number
one cause for cervical cancer, and things like that, but I don’t
Table 1
Qualitative themes and exemplar quotes.
Concept Theme Exemplar quotes
Sexual disinhibition
Sexual behaviors are independent of
vaccination
”…it’s case dependent. So you have those children who are going to be more at risk, but
you have a majority of the children who are not going to deal with those type of issues at
this early on age (male, 9 years in practice).”
“No. I’m really not…they’re going to do what they want to do anyway. It's a good time to
educate them, of course, but I’d rather just protect them. It doesn’t really give them a
license to do anything (male, 16 years in practice).”
Patients are unaware of what they’re
getting vaccinated for
“Kids don’t have an idea of what shots they really get… [Children] go glossy eyed and not
even listening…they’re just concerned about how many shots they’re getting, but they
don’t know what they’re for (female, 7 years in practice).”
No support for disinhibition in the
literature
“I think the literature doesn’t support that. I think there might be parents who think that,
but I think there's no evidence of it (female, 37 years in practice).”
Decrease in cervical cancer
screening
Physicians haven’t thought about it “I don’t know. I don’t know, actually. It's a good question. I’ve never suggested that, or
implied that, or even thought about it, so I would think that the patients probably haven’t
made that connection, would be my guess (female, 25 years in practice).”
“There are so many reasons why the girls that I vaccinate or the boys that I vaccinate are
going to fall out of care that the HPV vaccine has truthfully not crossed my worry (female,
19 years in practice).”
“I don’t know the data around this one- I haven’t looked for that data speciﬁcally (female,
9 years in practice).”
Women are unaware of the purpose of a
Pap smear
“I honestly don’t think most people know why they’re getting pap smears, but everybody
kind of expects to get one. So I haven’t experienced that or heard that at all with people
saying, ‘Oh, I don’t need to get pap smears now’ (female, 4 years in practice).”
“They’re not thinking about cervical cancer so we’re trying to explain what we’re doing it
for but I’m not sure they really make the connection. With us doing Pap smears at later
ages anyway, delaying the onset of Pap smears is really not in their mind anyway (male, 16
years in practice).”
Time lag between vaccination and Pap
testing
“No, because I think by the time our girls are going for Pap screens they are going to have
forgotten that they got HPV vaccines. So no, I don’t think it will. I don’t think it will impact
them getting Pap smears. I hope it won’t… I don’t know that it’s that deep (female, 14 years
in practice).”
“I think a majority of the kids I see that we do start the HPV are usually 10, 11, 12 so those
conversations, ten years from now when you’re going for you annual exams, don’t forget to
do this, this, and this, it's probably not going to be appropriate (male, 12 years in practice).”
“I don’t think that when they’re 21 years old, that link is – they’re thinking in their head,
‘Oh, well I got the shot 10 years ago, I’m not going to get my pap now.’ I just think that link
is too long (female, 7 years in practice).”
Women actually get over screened “They’re either good about getting their Pap smears and want to get them all the time
because we actually backed off from yearly Pap smears for a lot of people to every three
years, but still people want to come in every year and get their Pap smear, or people are
just not good about getting them anyway. I don’t think the vaccine affects that (male, 16
years in practice).”
“[F]olks are typically more resistant to the idea of not having enough Pap smears as op-
posed to feeling overprotected and not needing to go get a Pap smear (male, 6 years in
practice).”
“I actually think that a lot of people will default to getting screened more often than they
really need to. There’s still a lot of, like, you need an annual Pap myth that’s out there
among the providers and patient (female, 9 years in practice).”
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(female, 25 years in practice).” Another participant said they tell
their parents, “[Y]ou can certainly believe that you can control the
behavior of your child, but you certainly can’t control the behavior
of other peoples’ children and that’s what immunization is all
about; herd immunity (female, 14 years in practice),” indicating
that even if a parent states their child does not need it because
they will abstain from sexual activity until marriage, they cannot
predict the behavior of their child's future spouse. One HCP in-
dicated the opposite belief, stating that bringing up sexual activity
at a young age would make the parents more averse to
vaccination.
Some HCPs believed that in general, people who engage in
risky behaviors will do so regardless of vaccination status. One
said, “[T]he reasons why teenagers engage in sex, risky or not, are
really multi-factorial and the degree to which vaccination status
plays into it is probably zero-to-none (female, 9 years in practice).”
This quote echoes the sentiment expressed by most HCPs, that
vaccinating their patients was a good time to educate them aboutsafe sex but it was better to protect them if at all possible because
their decision to engage (or not engage) in risky behaviors was
independent of vaccination status.
3.2.2. Patients are unaware of which vaccine they are getting
One of the crucial components of risk compensation is that the
person engaging in the risky behavior has to be aware of what the
protective behavior is protecting them from and they have to
understand the connection between the risky behavior and the
protective behavior. If a patient is not aware that they are getting
vaccinated against HPV, not aware that HPV is sexually trans-
mitted, or not aware that the vaccine is protecting them against a
STI, then they will be unlikely to respond to vaccination with
riskier sexual behavior. Some HCPs indicated that many of their
patients do not know or pay attention to the vaccines being ad-
ministered. One participant in the study said, “My thoughts are
that most adolescents don’t know which vaccines they have or
haven’t gotten. And so the idea that they would [be] so aware of it
that it would inﬂuence their behaviors is a little far-fetched
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While none of the HCPs thought sexual risk compensation
happened, it should also be noted that none of them indicated that
it would inﬂuence their vaccination practices even if they did
think it happened. Generally, most of the HCPs seemed almost
exasperated when they were asked this question with one of them
asking, “Is it unprofessional for me to say that I think that's the
dumbest thing I’ve ever heard (male, 6 years in practice)?”.
3.3. Concern about a decrease in cervical cancer screening
In general, when we asked HCPs if they thought getting the
HPV vaccine would result in their patients feeling completely
protected from cervical cancer and therefore less likely to get
screened in the future, half (n¼11) said they did not know and
some (n¼3) stated they had not ever thought about it before. If an
HCP has not even thought about the possibility that their patient
might reduce cervical cancer screening, the idea that this might be
a reason an HCP would be hesitant to recommend the vaccine is
unfounded. Five of the HCPs said it was an interesting question,
indicating it could be an area for future research in order to edu-
cate HCPs on patient behavior post-vaccination in an attempt to
increase vaccine uptake.
When HCPs thought about it, all but one said they did not think
their patients would get screened for cervical cancer less often
after they were vaccinated. The HCP who did think patients would
get screened less stated it more as a fact that she thought they did
not need to be screened as much and that the guidelines would
probably change soon to allow for decreased screening frequency.
She said, “I don’t see why we should be doing as frequent cervical
or Pap smears if they have an effective vaccine to prevent cervical
cancer (female, 10 years in practice)”.
3.3.1. Women are unaware of the purpose of a Pap smear
The HCPs who did not think their patients would get screened
less frequently said they believed that most women do not un-
derstand the purpose of a Pap smear. Therefore, it would be un-
likely for the patient to make the connection that the HPV vaccine
protects against HPV, HPV causes cervical cancer, a Pap smear is a
screening test for cervical cancer, and they could therefore reduce
their screening. “I think they might make the connection with
cervical cancer because that's—I talk about that. But I don’t know
that they make a connection between that (HPV vaccination) and
not needing to get a Pap smear (female, 25 years in practice).”
3.3.2. Time lag between vaccination and Pap testing
There exists a time lapse of several years between the age of
vaccination (typically 11–12 years old) and when a woman should
start cervical cancer screening (21 years old). Most HCPs indicated
their patients will likely forget they are vaccinated against HPV
and what the vaccine protects against by the time they have to
make a decision about cervical cancer screening. “I would agree
that I think the teenagers aren’t thinking that far ahead. They have
risky behavior anyway, so I don’t know that this has anything to do
with it (female, 37 years in practice)”.
3.3.3. Women get over screened
Largely, HCPs indicated the problem they face with their pa-
tients is that they are screened too often, as opposed to not often
enough. They noted that most patients and HCPs are unaware of
the current guidelines and tend to think screening should occur on
a yearly basis. “That’s not something I’m particularly worried about
and I actually think that a lot of people will default to getting
screened more often than they really need to (female, 9 years in
practice)”. Some HCPs also noted that annual screening is just part
of a woman's routine and some patients feel uncomfortabledecreasing screening to every three years.
Even if a reduction in cervical cancer screening was identiﬁed,
HCPs indicated this would not inﬂuence their vaccination prac-
tices. They said they do not think their patients would get
screened less but if they did, the HCP would still want to vaccinate
as many people as possible. They stated preventing cancer is al-
most always better than screening and catching it early. One stated
that it is important to emphasize that to the patient and said,
“Discussing that even though you’ve had the HPV vaccine, this is—
this (cervical cancer) could still be an issue, so you need to get your
regular Pap screens (female, 3 years in practice).” Furthermore,
since there are many other reasons patients fall out of care, the
thought that they would choose not to continue to be screened for
cervical cancer based solely on having the HPV vaccination is
unlikely. “Like people that don’t get Paps, it’s not because they
don’t think they’re at risk it’s because they’re doing resource al-
location differently in terms of time and money and access to
healthcare (female, 9 years in practice).”4. Discussion
Opponents of the HPV vaccine have argued that the receipt of
the vaccine could cause adolescents to engage in more risky sexual
behavior due to a perceived decreased risk of sexually transmitted
infections [17]. Some clinicians have expressed concern that wo-
men who have received the HPV vaccine will be less likely to get
screened for cervical cancer, or will cease cervical cancer screening
altogether [19]. Since HCP recommendation is one of the strongest
predictors of HPV vaccine uptake, it is important to understand if
HCPs believe risk compensation occurs after HPV vaccination and
if this belief results in the HCP being hesitant to recommend the
vaccine. This is one of the ﬁrst studies to qualitatively analyze HCP
beliefs regarding risk compensation in the context of both sexual
behaviors and cervical cancer screening.
Our results indicate that none of the HCPs in our sample be-
lieved sexual risk compensation occurred as a result of HPV vac-
cination. The HCPs were up-to-date on current literature stating
that there is no evidence of increased risky sexual behaviors fol-
lowing HPV vaccination when examining both biological outcomes
and reported sexual behaviors [25–28]. HCPs tended to point the
interviewer to the literature regarding sexual behaviors, this
seemed to be an interesting way for the HCP to avoid giving their
own personal opinion on the matter. Furthermore, HCPs indicated
a concern about increased risky sexual behaviors would not result
in them being hesitant to offer the HPV vaccine to their patients.
HCPs also seemed to be unconcerned about a decrease in cer-
vical cancer screening behavior following HPV vaccination. Most
HCPs in this study indicated that they did not think patients would
decrease cervical cancer screening. They indicated several reasons
for this belief. The ﬁrst is that most women do not make a con-
nection between HPV, Pap smears, and cervical cancer. HCPs sta-
ted that frequently women tend to get over-screened for cervical
cancer and not under-screened. They also shared the belief found
in similar studies that vaccination and screening are both pre-
ventive health behaviors and a woman who engages in one is
more likely to engage in the other due to an emphasis on positive
health behaviors and access to healthcare. This is consistent with a
2015 study that found that unvaccinated womenwere actually less
likely to have had a recent Pap test as compared to vaccinated
women [29]. HCPs in this study indicated that even if they did
believe cervical cancer screening would decrease, it would not be a
reason to withhold vaccination. They stated preventing cancer is
better than screening so they would prefer to prevent it if at all
possible.
While this study is one of the ﬁrst of its kind to evaluate HCP
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are limitations to note. Participants were a convenience sample of
HCPs in an urban hospital system that generally serves minority
and economically disadvantaged patients and their responses may
not be representative of all HCPs. Additionally, this sample in-
cluded primarily female HCPs. Research has shown that having a
male HCP was associated with lower HPV vaccine initiation [30]
and that female HCPs were more likely to recommend HPV vac-
cine in a bivariate analysis [31]. This could mean our mostly female
sample had inherently more positive views toward HPV vaccine.
Selection bias also might have occurred as the HCPs who agreed to
participate might have different attitudes to vaccination than the
participants who did not wish to participate. Furthermore, the
face-to-face nature of the study might have contributed to HCPs
answering questions in a way they deemed socially desirable as
opposed to indicating their actual personal beliefs. This bias was
limited by assuring the participants their individual responses
would be kept in strict conﬁdence and all study information would
be de-identiﬁed.5. Conclusion
Overall, HCPs in this study indicated they were not concerned
about HPV vaccination leading to risk compensation. This was true
in the context of both risky sexual behaviors and decreases in
cervical cancer screening behaviors. This contradicts the ﬁndings
from previous research that indicated HCPs are reluctant to vac-
cinate due to a possible negative effects on cervical cancer
screening and risky sexual behaviors [20,32]. The reasons HCPs
cited for their lack of concern, including patients not knowing
what they have been vaccinated against, women not under-
standing the connection between HPV and Pap screening, and
women's preferences for over screening are areas that are neces-
sary to examine in future research. This study is the ﬁrst of its kind
to examine HCP beliefs regarding risk compensation following
HPV vaccination and adds to the growing body of literature that
there is not an increase in risky behaviors after vaccination and is
not a reason for non-vaccination.Conﬂict of interest statement
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